What is the projected market valuation for Bradykinin Mediated Angioedema by 2035?

The projected market valuation for Bradykinin Mediated Angioedema is expected to reach 3.868 USD Billion by 2035. Read More

What was the market valuation for Bradykinin Mediated Angioedema in 2024?

The market valuation for Bradykinin Mediated Angioedema was 1.154 USD Billion in 2024. Read More

What is the expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035?

The expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035 is 11.62%. Read More

Which companies are key players in the Bradykinin Mediated Angioedema Market?

Key players in the Bradykinin Mediated Angioedema Market include Takeda Pharmaceutical Company Limited, CSL Behring LLC, and Pharming Group N.V. Read More

What are the main types of angioedema segments in the market?

The main types of angioedema segments include Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. Read More

What was the market size for Hereditary Angioedema in 2024?

The market size for Hereditary Angioedema was 0.462 USD Billion in 2024. Read More

What is the projected market size for C1-Inhibitor Replacement Therapy by 2035?

The projected market size for C1-Inhibitor Replacement Therapy is expected to reach 1.577 USD Billion by 2035. Read More

How does the route of administration impact the Bradykinin Mediated Angioedema Market?

The route of administration includes Subcutaneous, Intravenous, and Oral, with Subcutaneous expected to reach 1.615 USD Billion by 2035. Read More

What demographic segments are considered in the Bradykinin Mediated Angioedema Market?

Demographic segments include Pediatric Patients, Adult Patients, and Geriatric Patients, with Adult Patients projected to reach 1.949 USD Billion by 2035. Read More

Bradykinin Mediated Angioedema Market

Q: What treatment options are available for Bradykinin Mediated Angioedema?

Available treatment options include C1-Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, and Antifibrinolytic Agents. Read More

ID: MRFR/HC/34260-HCR

128 Pages

Satyendra Maurya

Last Updated: April 24, 2026

Bradykinin Mediated Angioedema Market Research Report By Type (Hereditary Angioedema, Acquired Angioedema, Idiopathic Angioedema), By Treatment Options (C1-Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kalinate Therapy, Antifibrinolytic Agents), By Route of Administration (Subcutaneous, Intravenous, Oral), By Patient Demographics (Pediatric Patients, Adult Patients, Geriatric Patients) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Bradykinin Mediated Angioedema Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Hereditary Angioedema
4.1.2 Acquired Angioedema
4.1.3 Idiopathic Angioedema
4.2 Healthcare, BY Treatment Options (USD Billion)
4.2.1 C1-Inhibitor Replacement Therapy
4.2.2 Bradykinin B2 Receptor Antagonists
4.2.3 Kalinate Therapy
4.2.4 Antifibrinolytic Agents
4.3 Healthcare, BY Route of Administration (USD Billion)
4.3.1 Subcutaneous
4.3.2 Intravenous
4.3.3 Oral
4.4 Healthcare, BY Patient Demographics (USD Billion)
4.4.1 Pediatric Patients
4.4.2 Adult Patients
4.4.3 Geriatric Patients
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Takeda Pharmaceutical Company Limited (JP)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 CSL Behring LLC (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Pharming Group N.V. (NL)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Sobi AB (SE)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 BioCryst Pharmaceuticals, Inc. (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Eisai Co., Ltd. (JP)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Grifols S.A. (ES)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Amgen Inc. (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY TREATMENT OPTIONS
6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY TREATMENT OPTIONS
6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY TREATMENT OPTIONS
6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY TREATMENT OPTIONS
6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY TREATMENT OPTIONS
6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY TREATMENT OPTIONS
6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY TREATMENT OPTIONS
6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY TREATMENT OPTIONS
6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT OPTIONS
6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY TREATMENT OPTIONS
6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY TREATMENT OPTIONS
6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY TREATMENT OPTIONS
6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT OPTIONS
6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT OPTIONS
6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY TREATMENT OPTIONS
6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY TREATMENT OPTIONS
6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT OPTIONS
6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY TREATMENT OPTIONS
6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY TREATMENT OPTIONS
6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT OPTIONS
6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT OPTIONS
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT OPTIONS
6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT OPTIONS
6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT OPTIONS
6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY TREATMENT OPTIONS, 2024 (% SHARE)
6.112 HEALTHCARE, BY TREATMENT OPTIONS, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY TREATMENT OPTIONS, 2025-2035 (USD Billion)
7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Hereditary Angioedema
Acquired Angioedema
Idiopathic Angioedema

Healthcare By Treatment Options (USD Billion, 2025-2035)

C1-Inhibitor Replacement Therapy
Bradykinin B2 Receptor Antagonists
Kalinate Therapy
Antifibrinolytic Agents

Healthcare By Route of Administration (USD Billion, 2025-2035)

Subcutaneous
Intravenous
Oral

Healthcare By Patient Demographics (USD Billion, 2025-2035)

Pediatric Patients
Adult Patients
Geriatric Patients

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓